Interesting find, hump4. In addition to his AMRN connection,
that man has/had a number of interesting positions/jobs at PFE:
Executive Director, Head of Clinical Development Quality Performance and Risk Management
Mar 2014 – Present 5 years 8 months
New London/Norwich, Connecticut Area
-Accountable for the performance oversight of Pfizer's Good Clinical Practice (GCP) Quality Management System, Clinical Trial Quality and the Quality Analytics function across the portfolio, GCP processes and clinical trial vendors.
-Accountable for Pfizer's GCP Risk Management process, ensuring proactive risk management is embedded in clinical development.
-Accountable for the performance oversight of Pfizer's Good Clinical Practice (GCP) Quality Management System, Clinical Trial Quality and the Quality Analytics function across the portfolio, GCP processes and clinical trial vendors.
-Accountable for Pfizer's GCP Risk Management process, ensuring proactive risk management is embedded in clinical development.
Clinical Director- Cardiovascular
Jun 1998 – Jun 2002 4 years 1 month
Responsible for medical and research initiatives, clinical and basic, in the Northeastern US as related to cardiovascular/metabolic disease. Key responsibilities included medical and research support for Lipitor®, Norvasc®, Accupril®, Tikosyn®, opinion leader development, key academic institution partnership development, designing and overseeing phase III- IV clinical studies as well as the support of basic research grants in the areas of hypercholesterolemia and hypertension. Managed regional medical business issues that arose from the field and marketing colleagues by supplying medical and scientific expertise. Key interests included the development of partnerships to bring technology and novel research ideas into Pfizer’s clinical research and marketing programs.....
Spearheaded numerous key medical marketing programs to drive appropriate utilization and access to cardiovascular medicine.
Designed, developed and managed phase IIIB and IV clinical studies for Lipitor® (hyperlipidemia).....
^^^^^^^^^^^^^^^^^^
Scientific Advisor
Kaye Scholer LLP
Nov 1996 – Jun 1998 1 year 8 months
Scientific Advisor for matters related to IP litigation and IP strategy. Clients included major biotechnology and pharmaceutical companies[PFE among them].
Scientific Advisor for matters related to IP litigation and IP strategy. Clients included major biotechnology and pharmaceutical companies.
